National Heart, Lung, and Blood Institute Support of Cellular Therapies Regenerative Medicine

2012 ◽  
pp. 403-423
Author(s):  
Traci Heath Mondoro ◽  
John Thomas
Keyword(s):  
Regenerative Medicine ◽  
Cellular Therapies ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung

scholarly journals An Update from the United States National Heart, Lung, and Blood Institute‐funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy

2014 ◽  
Vol 7 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Deborah Wood ◽  
Robin Wesselschmidt ◽  
Peiman Hematti ◽  
Adrian P. Gee ◽  
Cliona Rooney ◽  
...  
Keyword(s):  
United States ◽  
Cell Therapy ◽  
The United States ◽  
Cellular Therapies ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung

Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop

2020 ◽  
Vol 16 (12) ◽  
pp. 1714-1733
Author(s):  
Berislav V. Zlokovic ◽  
Rebecca F. Gottesman ◽  
Kenneth E. Bernstein ◽  
Sudha Seshadri ◽  
Ann McKee ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Neurological Disorders ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung

scholarly journals 4369 Reprogramming of vascular smooth muscle cells to multipotent progenitor cells contributes to progression of atherosclerosis

2020 ◽  
Vol 4 (s1) ◽  
pp. 102-102
Author(s):  
Allison Milfred Dubner ◽  
Sizhao Lu ◽  
Austin Jolly ◽  
Keith Strand ◽  
Marie Mutryn ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Progenitor Cells ◽  
Coronary Arteries ◽  
Lineage Tracing ◽  
Plaque Progression ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung

OBJECTIVES/GOALS: Our lab previously identified a population of vascular smooth muscle (SMC)-derived progenitor cells (AdvSca1-SM) which expand robustly in response to disease and can differentiate into multiple cell types. We now aim to define the role of these AdvSca1-SM cells in atherosclerotic plaque progression. METHODS/STUDY POPULATION: Goal one uses SMC lineage tracing mice and a model of atherosclerosis to track reprogramming of SMCs to AdvSca1-SM cells in the setting of disease. Arteries are analyzed using flow cytometry and immunofluorescence to quantify changes in number of mature SMCs and AdvSca1-SM cells. Goal two uses AdvSca1-SM lineage tracing mice with high cholesterol-induced atherosclerosis and plaque neovascularization. Arteries are analyzed to quantify expansion of AdvSca1-SM cells, subsequent re-differentiation into mature SMC, endothelial cells, or macrophages, and contribution to plaque neovascularization. Mechanistic findings from both goals are being investigated in diseased human coronary arteries. RESULTS/ANTICIPATED RESULTS: Flow cytometry from SMC lineage tracing mice revealed a 7- to 13-fold expansion of AdvSca1-SM cells in carotid arteries (p<0.001) and aortas (p = 0.03) after 6 weeks of western diet; no differences in macrophage numbers were observed. Additional SMC and AdvSca1-SM cell lineage tracing mice are on atherogenic diets to assess early and advanced atherosclerosis. We predict that AdvSca1-SM cells will contribute to macrophage accumulation as well as plaque neovascularization in the setting of severe atherosclerosis. Translational relevance of mechanisms driving SMC reprogramming and AdvSca1-SM cell contribution to plaque progression are being applied to studies of diseased human coronary arteries. DISCUSSION/SIGNIFICANCE OF IMPACT: Our data suggest a role for AdvSca1-SM cells in atherosclerosis. Ongoing work will clarify the mechanisms driving plaque-associated AdvSca1-SM expansion and define the ultimate fates of these cells. In vivo modulation of this process could provide the basis for future anti-atherosclerotic therapies. CONFLICT OF INTEREST DESCRIPTION: AD - CCTSI TOTTS TL1TR002533; SL - 18POST34030397 from the American Heart Association; AJ – no conflicts; KS - 1F31HL147393 from the National Heart, Lung, and Blood Institute, NIH; MM – no conflicts; RT – no conflicts; KSM – no conflicts; RAN - R01CA236222 from the National Cancer Institute, NIH, and 2018-03 from the Lungevity Foundation; and MCMW-E - R01 HL121877 from the National Heart, Lung, and Blood Institute, NIH, and 25A8679 from the Chernowitz Foundation.

Sign in / Sign up

Export Citation Format

Share Document